[The reactogenicity and immunogenicity of the first Cuban vaccine against human leptospirosis].
A controlled double-blind trial was conducted with the participation of 80 adult volunteers of both sexes, who were randomly divided into groups of 40 individuals each one. The case-base study received the vaccine and the control group was administered placebo to know the safety, the behaviour of reactogenicity, and to star the immunogenicity studies of the first Cuban vaccine against human leptospirosis. The vaccine used in the case-base study was an inactivated and trivalent vaccine containing strains of Leptospira canicola, icterohaemorrhagiae and pomona, since they have the highest circulation in the country. The results obtained showed the inocuity of the vaccine as no adverse severe reactions were detected. The general symptomatology observed was low, where as febricula was the most common general symptom. It appeared during the first 3 days of observation and there were no significant differences between the 2 group. Only a mild pain at the site of the injection was reported as a local symptom, which was more frequent in the vaccinated group than in the control group (7.8 against 1.5%, respectively). The seroconversion obtained was of 29% by microagglutination, and of 34.2% by ELISA. The final results allowed to conclude that this vaccine is safe for human adults at the ages under study, and give the possibility to continue other studies in more advanced stages to complete the requirements for obtaining its license.
Martínez Sánchez
R
R
Instituto de Medicina Tropical Pedro Kourí, Ciudad de La Habana, Cuba.
Obregón Fuentes
A M
AM
Pérez Sierra
A
A
Baly Gil
A
A
Díaz González
M
M
Baró Suárez
M
M
Menéndez Capote
R
R
Ruiz Pérez
A
A
Sierra González
G
G
López Chávez
A U
AU
D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood; D001428:Bacterial Vaccines / Q000009:adverse effects* / Q000276:immunology*; D016022:Case-Control Studies; D003462:Cuba; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007921:Leptospira interrogans / Q000276:immunology*; D041341:Leptospira interrogans serovar canicola / Q000276:immunology*; D007922:Leptospirosis / Q000517:prevention & control*; D008297:Male; D013997:Time Factors; D014895:Weil Disease / Q000517:prevention & control*
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines